Telix Pharmaceuticals Ltd — Capital/Financing Update 2018

Feb 8, 2018

==> picture [142 x 79] intentionally omitted <==

Notice of release of securities from Mandatory Escrow

Appendix 3B correction

Melbourne (Australia) – 9[th] February 2018 . Pursuant to ASX Listing Rule 3.10A, Telix Pharmaceuticals Limited (ASX.TLX) (“ Telix ”, the “ Company ”) advises that 2,937,500 shares which were classed as restricted securities and subject to ASX-imposed mandatory escrow at Listing are due be released from mandatory escrow on 5 March 2018. An application for quotation of these shares (Appendix 3B) will be made on 5 March 2018.

Summary of ongoing voluntary escrow arrangements

In addition to ongoing ASX-imposed mandatory escrow restrictions, as at today’s date, the total number of shares subject to voluntary escrow is 51,635,586, representing 26.15% of the Company’s total issued shares. Of these:

• 12,692,308 shares are subject to voluntary escrow until 15 February 2018 (i.e. 3 months from Telix’s listing on ASX on 15 November 2017);

• 32,918,663 shares are subject to voluntary escrow until 15 November 2018 (i.e. 12 months from listing);

• 384,615 shares are subject to voluntary escrow until 15 November 2019 (i.e. 24 months from listing); and

• 5,640,000 shares are subject to voluntary escrow for up to 48 months from listing (decreasing by equal increments of 1,410,000 Shares on 15 November of each year).

Appendix 3B correction

The Appendix 3B lodged on 15 January 2018 incorrectly noted that the Company had 194,500,000 fully paid ordinary shares quoted on the ASX. This number inadvertently included shares which are issued but remain unquoted as they are subject to continued ASX-imposed mandatory escrow restrictions.

The total number of Telix shares on issue is 197,437,500. The number of quoted securities at the current date is 127,108,087.

About Telix Pharmaceuticals Limited

Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX).

For more information visit www.telixpharma.com.

==> picture [142 x 79] intentionally omitted <==

Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited Email: chris@telixpharma.com

Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au